Aimovig has an effective half-life of 28 days, meaning it takes about that long for half the drug to leave your body. For full clearance, you’re looking at roughly four to five months after your last injection before the medication is essentially gone from your system.
How the 28-Day Half-Life Works
A drug’s half-life tells you how long it takes for your body to eliminate half of what’s circulating. With Aimovig’s 28-day half-life, if you take a dose on day one, half of it remains after four weeks, a quarter after eight weeks, an eighth after twelve weeks, and so on. The general rule in pharmacology is that a drug is considered cleared after about five half-lives. For Aimovig, that comes out to approximately 140 days, or just under five months.
This doesn’t mean you’ll feel the drug’s full effects for that entire period. As levels drop below a certain threshold, the medication stops blocking enough receptors to meaningfully prevent migraines. Many people notice their migraine pattern starts to shift within one to two months of stopping. But trace amounts of the drug remain in your bloodstream for longer than that.
Why It Stays So Long Compared to Other Drugs
Aimovig isn’t processed the way most medications are. Typical pills get broken down by your liver or filtered through your kidneys, which clears them in hours or days. Aimovig is a monoclonal antibody, a large protein molecule, and your body handles it more like it would any other protein. It gets broken down gradually through general proteolytic degradation, the same process your body uses to recycle its own proteins. Your liver and kidneys play essentially no role in clearing it, which is why kidney or liver problems don’t change how long it stays in your system.
The drug actually clears through two overlapping pathways. At lower concentrations, Aimovig gets eliminated mainly by binding to its target receptors (the ones involved in migraine signaling) and being absorbed along with them. At higher concentrations, the nonspecific protein breakdown pathway handles most of the work. This creates what pharmacologists call nonlinear kinetics: the drug doesn’t clear at a perfectly steady rate, but the 28-day half-life captures the overall pattern.
Does the Dose Matter?
Aimovig comes in 70 mg and 140 mg doses. The half-life is 28 days for both. A higher dose means more of the drug is present initially, so it takes slightly longer in absolute terms for every last molecule to clear. But the difference is modest. If you’re on the 140 mg dose, expect clearance to take a few extra weeks compared to the 70 mg dose, not months longer.
Because of the nonlinear elimination pattern, the higher dose doesn’t simply result in double the blood levels. More of the drug gets routed through the general protein breakdown pathway at higher concentrations, which partially compensates. In practical terms, both doses follow a similar overall timeline for leaving your system.
What This Means If You’re Stopping
If you’re discontinuing Aimovig because of side effects, the most common question is how long those side effects might linger. Since the drug takes months to fully clear, side effects like constipation or injection-site reactions typically fade gradually rather than stopping abruptly. Most people report improvement within four to eight weeks after their last dose, as circulating levels drop below the effective range.
If you’re switching to a different migraine prevention medication, the long clearance window means Aimovig will overlap with your new treatment for a while. This is generally not a concern for most drug combinations, but it’s worth knowing that both are active in your body simultaneously during that transition.
Factors That Don’t Change the Timeline
Because Aimovig bypasses the liver and kidneys entirely for its elimination, several factors that would normally speed up or slow down drug clearance simply don’t apply here. Mild to moderate kidney impairment has no measurable effect on how quickly Aimovig leaves your body. The same goes for liver function. Clinical data from FDA studies confirmed that patients with reduced kidney function cleared the drug at the same rate as those with normal function. Severe kidney impairment (below 30 mL/min filtration rate) hasn’t been formally studied, but based on the drug’s elimination mechanism, it’s not expected to matter either.
Your age, sex, and body weight can cause minor variations in blood levels, but none of these factors dramatically change the 28-day half-life or the overall four-to-five-month clearance window. The timeline is remarkably consistent from person to person, which is one advantage of how monoclonal antibodies are processed compared to traditional small-molecule drugs.